OpenAI CEO Testifies in Senate Hearing on AI Safety, Marking a Historic Moment for the Future of Technology.

OpenAI CEO Sam Altman recently spoke alongside NYU professor Gary Marcus and IBM’s chief of trust, Christina Montgomery, before a Senate Judiciary subcommittee in Altman’s first official appearance before Congress. The session, described as “historic” focused on understanding the potential threats posed by generative AI models (such as ChatGPT) and how lawmakers should approach regulation. Altman advocated for the establishment of a federal oversight agency with the authority to issue and revoke development licenses and believed that creators should be compensated when their work is used to train an AI system. He agreed that consumers who suffer harm using AI products should be entitled to sue the developer. During the hearing, Gary Marcus warned that nobody currently understands or can predict how harmful existing AI products can be or will become, advocating a cautious approach involving greater transparency. The speakers also agreed with members of Congress that the U.S. needed a national privacy law similar to those in Europe. However, one of the lone sources of discord came from IBM’s Christina Montgomery, who disagreed with the notion that a new federal agency would be necessary to enforce regulations in the AI industry.

J-S Tremblay
About the author - J-S Tremblay

I've been involved in the cryptocurrency world since 2016 and trading since 2019. I started Moon and Lambo in 2021. I'm passionate about crypto and love to share my knowledge. I hate bankers and I hope that cryptocurrency will change the financial world for the better. View full profile...

View J-S Tremblay website

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top
Hard disk drives (hdd) : storage powerhouses for your digital world. All users can see, edit, or delete their personal information at any time (except they cannot change their username). Pharmacy executives file buddy briefing urging appeals court docket to preserve fda approval.